



Contents lists available at ScienceDirect

Journal of King Saud University – Science

journal homepage: www.sciencedirect.com

Original article

Molecular characterisation of *csgA* gene among ESBL strains of *A. baumannii* and targeting with essential oil compounds from *Azadirachta indica*

Anu Iswarya Jaisankar^a, A.S. Smiline Girija^{a,*}, Shoba Gunasekaran^b, J. Vijayashree Priyadharsini^c^a Department of Microbiology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences [SIMATS], Saveetha University, P.H.Road, Chennai, Tamilnadu 600077, India^b Department of Biotechnology, DG Vaishnav College of Arts and Science, Chennai, Tamilnadu 600106, India^c Research Scientist, BRULAC, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences [SIMATS], Saveetha University, P.H.Road, Chennai, Tamilnadu 600077, India

ARTICLE INFO

Article history:

Received 7 April 2020

Revised 16 September 2020

Accepted 27 September 2020

Available online 6 October 2020

Keywords:

A. baumannii

Biofilm

csgA gene*A. indica*

ABSTRACT

Objectives: *A. baumannii* is considered as a “red alert” nosocomial human pathogen and exhibits an extensive antibiotic resistance spectrum. The biofilm formation mediated by the *csgA* is a potent virulence factor in *A. baumannii* and targeting the same would be of a novel strategy to control *A. baumannii* infections. The aim of the present study is thus to evaluate the anti-biofilm activity of essential bio-compounds from *Azadirachta indica* against the ESBL producing strains of *A. baumannii* by *in-vitro* and *in-silico* studies.

Methods: Biofilm formation by Semi-quantitative adherence assay was performed for the 73 strains of ESBL producing *A. baumannii*. Genomic DNA was extracted and molecular characterization of *csgA* gene was done by PCR amplification with further sequencing. *In-vitro* anti biofilm assay from crude extract of *A.indica* was performed which was then followed by the *in-silico* docking involving retrieval of *csgA* protein and ligand optimisation, molinspiration assessment on drug likeliness, docking simulations and visualisations.

Results: Biofilm assay showed 58.9%, 31.5% and 0.09% as high grade, low grade and non-biofilm formers respectively. 20.54% (15/73) of the screened genomes showed positive amplicons for the *csgA* gene associated with biofilm formation among the ESBL producing strains of *A. baumannii*. All the ceftazidime, cefipime and cefotaxime resistant strains showed the presence of *csgA* gene (100%; 15/15), followed by 46.6% (7/15) resistant isolates for ceftriaxone. *In-vitro* crystal violet viability assay showed MBEC₅₀ and MBEC₉₀ at a concentration of 20 μ l and 40 μ l respectively. *In-silico* assessments on the essential oil compounds from neem showed imidazole to exhibit the highest interaction with least docking energy and high number of hydrogen bonds.

Conclusion: The current study emphasises that imidazole from *A.indica* to be a promising candidate for targeting the *csgA* mediated biofilm formation in ESBL strains of *A. baumannii*. However, further *in-vivo* studies have to be implemented for the experimental validation of the same.

© 2020 The Authors. Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* Corresponding author at: Department of Microbiology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences [SIMATS], Saveetha University, P.H. Road, Chennai, Tamilnadu 600077, India.

E-mail address: smilinejames25@gmail.com (A.S. Smiline Girija).

Peer review under responsibility of King Saud University.



Production and hosting by Elsevier

1. Introduction

Acinetobacter baumannii is a small, rod shaped, non-motile, non-fermentative, gram negative bacterium (Beijerinck, 1911). The bacterium has been designated as a “red alert” human pathogen, because of its extensive antibiotic resistance spectrum. In recent years, They are generating a great alarm among the medical fraternity. Indeed, the World Health Organization (WHO) has recently identified MDR pathogens within the acronym ESKAPE pathogens (Cerqueira and Peleg, 2011; Rice, 2008). *A. baumannii* has a high incidence among immuno-compromised individuals, particularly

those who have experienced a prolonged (>90 d) hospital stay (Montefour et al., 2008). The cross-transmission of microorganisms from abiotic surfaces has got a significant role in the ICU-acquired infections. Its ability to withstand desiccation and starvation by producing biofilms as a community of bacteria enclosed within a protective polymeric matrix is considered to be an important factor that attributes to the spread of *A. baumannii* in these environments (Russotto et al., 2015; D'Agata et al., 1999; Boyce, 2007; Jawad et al., 1996, 1998a, 1998b). The biofilm formation is a potent virulence factor in *A. baumannii* as it increases the survival rate of this bacterium in its persistence in the hospital environment, increasing the probability of causing nosocomial infections and outbreaks. Extended-spectrum β -lactamases is a rapidly evolving group of enzymes capable of degrading the majority of β -lactam antibiotics such as third-generation cephalosporins and aztreonam. The incidence of infections caused by ESBL producing pathogens is increasing every year, mainly because of inadequate antimicrobial therapy (Będzichowska et al., 2019).

It is exciting to note that in the initiation and progression of biofilm formation by *A. baumannii*, the bacterium produces an extracellular matrix consisting of curli amyloid fibers and cellulose. Curli fibers bring about adhesion to surfaces, cell aggregation, and biofilm formation. Curli fibers are potent host inflammatory response inducers and also mediate host cell adhesion and invasion (Barnhart and Chapman, 2006). Curli-specific gene (*csg*) operons encode the major structural components and accessory proteins and contribute to the Curli fiber production. The export of *csg* proteins to the outer surface is guided by the accessory proteins, *csgG*, *csgE* and *csgF* (Jain et al., 2017). *csgA* gene, the major subunit of the curli amyloid fiber, is synthesized in the cytoplasm and transported as an unfolded protein to the cell surface, where upon interaction with the *csgB* nucleator protein, assembles to form extracellular amyloid polymers (Hammar, Bian and Normark, 1996; Hammar, Schmidt and Chapman, 2007) substantiating the role of *csgA* in the bio-film formation.

Thus targeting *csgA* would be a novel therapeutic approach to combat the menace of drug resistant strains of *A. baumannii*. Amidst many natural plants in India, *Azadirachta indica* is considered as a medicinal plant in abundance and the phytochemical analysis of the same had documented the presence of alkaloids, tannins, glycosides, saponins, flavonoids and terpenoids (Sudevan et al., 2013). In many overviews on the bio-active constituents from *A. indica*, various compounds were known for their antimicrobial, anti-inflammatory and anti-oxidant properties (Alzohairy, 2016). With this background the present study is intended to molecularly characterize the presence of *csgA* gene among the multi-drug resistant strains of *A. baumannii*, together with the *in-vitro* and *in-silico* docking analysis of the bio-active compounds from *A. indica* against *csgA*.

2. Materials and methods

2.1. Semi-quantitative adherence assay for the detection of biofilm formation

73 ESBL producing strains of *A. baumannii* reported in our earlier studies (Kouidhi et al., 2010) were cultured separately in a 96-well flat bottomed microtitre plate was used for culturing as reported in earlier studies (Kelleher and Broin, 1991). With 200 μ l of the fresh broth culture in trypticase soy broth (HiMedia, Mumbai, India) with 0.25% glucose (w/v), the assays were done in triplicate for each strain. Then at 37 °C/24 hrs with negative control (broth + 0.25% glucose) and positive control (known biofilm forming strain of *A. baumannii* earlier detected), the plates were incubated. To remove the free cells, the incubated wells were

washed three times with phosphate buffered saline (PBS) and with 95% ethanol/5min the adhered bacteria were fixed and dried. Finally the wells were stained with 100 μ l of 1% w/v crystal violet solution (HiMedia), for 5 mins. Distilled water was added to remove the excess stain and the wells were dried. Biofilm positive and negative strains of *A. baumannii* were used as the standards for validation of the biofilm production. Optical density was measured in the plate reader at 570 nm (OD_{570}), and the biofilm formation was recorded as high ($OD_{570} \geq 1$), low ($0.1 \leq OD_{570} < 1$) or negative ($OD_{570} < 0.1$) (Avila-Novoa et al., 2019).

2.2. Extraction of genomic DNA

73 multi-drug resistant strains of *A. baumannii* which were maintained in 80%/20% (v/v) glycerol in LB medium at –80 °C from our repertoire used in our earlier studies were retrieved (Smiline, Vijayashree and Paramasivam, 2018). Fresh cultures were prepared on MacConkey agar by incubating at 37 °C/24 h. Qiagen DNA extraction Kit was used in the extraction of genomic DNA which was carried in accordance to the manufacturer's instruction and was stored at –20 °C until further use.

2.3. PCR amplification of *csgA* gene and sequencing

The primer sequences ACTCTGACTTGACTATTACC and GATGCAGTCTGGTCAAC (Zeighami et al., 2019) were annealed at 50 °C for 36 cycles in a thermal cycler (Eppendorf Mastercycler, Germany). Briefly, 15 μ l of the genomic DNA was resolved with the help of 1.5% agarose gel containing ethidium bromide in Tris borate buffer at 90v for about 40 min jointly with a suitable 1.5 Kbp DNA ladder as marker. Big dye terminator cycle sequencing kit, bioedit sequence analyser and 3730XL genetic analyser were used for bidirectional sequencing of *csgA* amplicon product which in turn is done by alignment of sequences from the forward and reverse primers. Finally BLAST analysis is done for similarity check of nucleotides. The sequences were then aligned by ClustalW software for multiple sequence alignment using default parameters.

2.4. *In vitro* anti – biofilm assay with *A. indica* essential oils

2.4.1. Plant source

Plant sources were obtained from the aerial leaves of *A. indica* and they were subjected to hydro distillation for the extraction of essential oils. Anhydrous sodium sulfate was added to remove the excess water from the extracted oil and was stored in dark vials at 4 °C.

2.4.2. Anti-biofilm assay

A 96 well polystyrene flat bottom plate was used to check the anti-biofilm formation of the crude extracts from *A. indica* on *A. baumannii* as described in earlier studies (Sánchez et al., 2016). Briefly, sterile trypticase soy broth was used for the preparation of fresh broth suspension of *csgA* positive of *A. baumannii* and the suspension was adjusted to 0.5 Mc Farland standards. For comparative purposes, control wells with only medium, organism and oil suspensions (5 μ l to 40 μ l) were prepared. Incubation of the plates was done at 37 °C for 24 hrs. Then, the supernatant was removed and to remove the free floating cells, each well was washed with sterile distilled water and was air dried for 30 min. 1% of aqueous solution of crystal violet was used for staining and was allowed to stand for 15 min. Then the stain was removed thrice by washing with distilled water. 250 μ l of ethanol was used for solubilizing the wells and a plate reader was used at 570 nm to measure the absorbance. The equation $1 - (\text{test } OD_{570} / \text{Control } OD_{570}) / 100$ was used for calculating the inhibition percentage (Gowrishankar

et al., 2016). The minimum biofilm inhibition concentration is that which showed 50% and 90% inhibition of biofilm formation.

2.5. Retrieval of *csgA* and protein optimisation

The crystal structure of *csgA* protein was obtained from the RCSB protein data bank (<http://www.rcsb.org/pdb>). The optimisation of crystal structure of *csgA* is done by the addition of hydrogen atoms. Kollman united atoms force field was used to assign electronic charges to the protein atoms which was done in Auto Dock tool – 1.5.6 and the RASMOL tool was used for the visualisation of three dimensional structure of *csgA* protein.

2.6. Ligand preparation and optimisation

The structures of the bio-active derivatives of *A. indica* was obtained from the chemsketch software. The generated 3D structures were then optimised. The selected ligands were subjected to subsequent conversions by open label molecular converter program. They were then saved in PDB format. The selected ligands were further saved in .mol file.

2.7. Molinspiration assessment of the molecular properties of the selected compounds

The counts of hydrogen bond acceptors and donors in relation to the membrane permeability and bio-availability of the compounds, logP for partition co-efficient, molecular weight of compounds of the basic molecular descriptors were assessed with the help of molinspiration assessment program. The characters of absorption, distribution, metabolism and elimination of the selected bio compounds were further evaluated on the basis of “The Lipinski’s rule of five” (Benet et al., 2016).

2.8. Docking simulations

Auto Dock tool was used for docking analysis to interpret the affinity between bio-compounds of *A. indica* against *csgA* protein of *A. baumannii*.

2.9. Docking visualisation

Using Discovery studio visualiser, the hydrogen bond interaction between the bio-compounds of *A. indica* against *csgA* of *A. baumannii* were visualised. With further docking score assessments, binding affinities, molecular dynamics and energy simulations, the relative stabilities were evaluated.

2.10. Statistical analysis

The SPSS version 21.0 (Chicago, IL) was used for assessing the statistical significance of the results obtained. At a *p*-value < 0.05, the Chi-square test and Fisher’s exact 2 - tailed tests were applied. Pearson’s correlation analysis was performed to co-relate the frequency of *csgA* among the ESBL strains of *A. baumannii*.

3. Results

3.1. Molecular characterization of *csgA* gene and its correlation with ESBL’s

Semi-quantitative adherent bioassay for biofilm formation showed 58.9% (43/73), 31.5% (23/73) and 0.09% (7/73) as high grade, low grade and non-biofilm formers. All the 43 strains of high grade biofilm formers showed resistance against ceftazidime,

cefipime and cefotaxime and 76.7% (33/43) showed resistance against ceftriaxone. All the low grade biofilm formers showed resistance against ceftazidime, cefipime and cefotaxime. 20.54% (15/73) of the screened genomes showed positive amplicons for the *csgA* gene associated with biofilm formation among the ESBL producing strains of *A. baumannii* (Supplementary Fig. 1). The selection of the ESBL strains were done based on the earlier studies (Smiline et al., 2018; Rawat and Nair, 2010). A positive value was obtained on Pearson correlation analysis which suggest the correlation of occurrence of *csgA* gene with ESBL strains (*p*-value < 0.05). The presence of *csgA* gene was found to be (100%; 15/15) in all the ceftazidime, cefipime and cefotaxime resistant strains, followed by 46.6% (7/15) resistant isolates for ceftriaxone.

3.2. Anti-biofilm assay results

Crude extract of *A. indica* showed minimal biofilm eradication concentration (MBEC₅₀) at 20 µl concentration on crystal violet assay indicating 50% inhibition of biofilm formation by *A. baumannii* (*p* < 0.05). Similarly, they showed MBEC₉₀ at 40 µl concentration indicating 90% inhibition of biofilm formation (Fig. 1).

3.3. Structural retrieval of the *csgA* protein from *A. baumannii*

FASTA sequence of *csgA* from *A. baumannii* was retrieved from UNIPROT database and its sequence ID was A0A335NTF8. Using the Swissmodel server, homology model was made with 5WQO – A chain as template (Fig. 2). The model was highly plausible with 100% sequence identity with the template. Besides, the Ramachandran plot showed 95.9% of residues in most favoured regions and with no residues in disallowed region (Fig. 3). The 3D structure of *csgA* was visualized using RASMOL with the pink colour denoting the alpha-helix, yellow arrow denoting the beta sheets and white colour denoting the turns.

3.4. Structural retrieval of the ligands from *A. indica* essential oil compounds

ACD Chemscketch was used for achieving the ligand optimization and Open Babel molecular converter tool was used in retrieving the compatible format. The 2D and 3D structures of the ligands from *A. indica* retrieved, and its SMILES format, are shown in Table 1.

3.5. Molinspiration assessment towards drug likeliness

Based on the calculation of the ion channel modulation, GPCR ligand, nuclear receptor ligand, kinase inhibitor, enzyme inhibition and protease inhibition, the bioactivity score prediction of essential compounds of *A. indica* against *csgA* of *A. baumannii* towards drug likeliness was assessed and tabulated (Table 2).

3.6. Docking analysis of the *A. indica* derivatives against *csgA* of *A. baumannii*

LGA was used for selecting the best conformers. The bond interactions between the essential compounds from *A. indica* and *csgA* of *A. baumannii* in the stick model by discovery studio visualisations between the selected compounds are shown in Fig. 4. The *csgA* protein interactions with bio-active compounds from *A. indica* are shown in Table 3. The docking scores, number of hydrogen bonds formed, torsional energy between the ligands and the drugs were recorded (Table 4). The overall docking energies and interactions between the *csgA* and the *A. indica* biocompounds were assessed based on the ligand efficiency, intermolecular energy, electrostatic energy, vdW + Hbond + desolv energy, internal energy




Fig. 1. Anti-biofilm assay showing MBEC₉₀ at 40 µl concentration indicating 90% inhibition of biofilm formation using strain control, medium control, oil suspension control.



Fig. 2. Prediction of csgA structure and homology modelling in Swissmodel Server.

and torsional energy in kcal/mol (Table 5). The data also showed the least binding energy, van der Waals, π - σ interactions, alkyl/ π -alkyl interactions, π -sulphur interactions and imidazole compound was assessed as the promising interacting compound from *A. indica*.

4. Discussion

The potent virulence factor of *A. baumannii* is its ability to form biofilms in a four major step process viz., attachment of bacteria to the surface, formation of micro-colony, maturation of biofilms and




Fig. 3. Validation of the predicted structure using Ramachandran plot.

finally its detachment leading to further colonisation. In *A. baumannii*, formation of biofilm is mediated by cell to cell adhesion through curli fibers, ascribing the virulence and pathogenicity. Thus the present study is intended to molecularly characterise the *csgA* gene and the association of its frequency with the ESBL producing strains of *A. baumannii*. Curbing the development of biofilms would be an alternate alternative strategy to battle against the drug resistant strains of *A. baumannii*. Our study had thus assessed the anti-biofilm activity of the *A. indica* extract against *csgA* positive strains of ESBL producing *A. baumannii*.

Earlier studies demonstrate the occurrence of genotypic detection of putative virulent factors like *csgA* from *A. baumannii* to be 63.63% (Tavakol et al., 2018). Another study had reported the occurrence of *csgA* gene to be about 70% (Darvishi, 2016). A study by Daryanavard et al., had reported the occurrence of the same to be about 55% (Daryanavard and Safaei, 2015). Another study in Iran reported the incidence of *csgA* gene to be 12.39% which is lower than our studies (Momtaz et al., 2015). In view with this, our study shows about 20.54% occurrence of the *csgA* gene substantiating the correlation of the same with the ESBL producing strains of *A. baumannii*. In contradiction a study shows no occurrence of *csgA* among multi drug resistant strains which highlights the role of some other genes ascribing the same (Zeighami et al., 2019). So, it is obvious that the *csgA* gene associated biofilm production may vary in its expression and thus requires periodical monitoring to further probe into the insights of its potent virulence role.

We also assessed the anti-biofilm effect of *A. indica* bio-compounds in the present study as many earlier reports had detailed the characterization of phenolic compounds up to its structural elucidations (Mistry et al., 2014). Anti-biofilm assay was proceeded with the crude extracts rather than the purified

compounds for the *in-vitro* analysis. The oil treated and the oil untreated groups on comparison showed anti-biofilm effect significantly ($p < 0.05$). For the *in-vitro* assessments of the anti-biofilm activity, we employed the gold standard crystal violet staining method as it is highly cost effective, adaptable and less time consuming method (Singaravelu et al., 2019). Earlier studies had no documentation on the anti-biofilm activity of *A. indica* against the ESBL strains of *A. baumannii*, this study intends to give an insight of biofilm inhibition on the same in *csgA* producing ESBL-*A. baumannii*.

Selection of the bioactive compounds from *A. indica* was based on the detailed analysis from earlier literatures (Chaichoo Wong et al., 2017). The essential oil compounds from *A. indica* had been selected for *in-silico* assessments, as they encompass potent hydrophobic biomolecules and are highly suitable for nano-formulations based on earlier reports (da Costa et al., 2014). We did not perform the purification protocols and thus the study limits itself with the anti-biofilm activity done only with the crude extracts. With the aid of the computational bio-informatics tools and databases, the best fit of the compounds to target the *csgA* was achieved efficiently. Based on the strength score and pose, a promising ligand – receptor complex was obtained. From the molinspiration results, the drug likeliness was promising with no violations for all the selected bio-compounds except bis (2-propylpentyl) phthalate ester.

Comparing the molecular weight of all the compounds, imidazole-2-carboxylic acid possessed the least molecular weight of 126.11 and bis (2-propylpentyl) phthalate ester possesses the higher molecular weight of 390.36. Other compounds showed a molecular weight ranging between 200 and 370. Assessments on the hydrogen bonds donor and acceptor property, bis (2-propylpentyl) phthalate ester had the greatest number of rotatable bonds of about 16 together with the greatest *miLogP* value of -0.17 . The TPSA value (Topological Polar Surface Area) of a compound is an important evaluation, as it attributes to the oral bio-availability of drugs which should be <140 Å. It is promising to note that all the 6 bioactive compounds that we have selected showed TPSA values of <140 Å.

Evaluation of the overall docking energies showed that imidazole-2-carboxylic acid got the greatest number of hydrogen bonds while bis(2-propylpentyl) phthalate has got the least. Trihydroindole shows the least binding energy of -9.39 whereas bis(2-propylpentyl) phthalate show about -4.07 . Dehydrodiisoeugenol possessed a greatest inhibition constant whereas imidazole-2-carboxylic acid showed the least inhibition constant. Ligand efficiency, electrostatic and torsional energy were found to be greater in bis(2-propylpentyl) phthalate ester.

We can also infer from the overall interaction that imidazole-2-carboxylic acid showed 7 hydrogen bond interactions, 4 vanderwaal's interactions, 1 π – σ interaction and 1 π – alkyl interaction which states the stabilisation of the binding structures. This was followed by 3-Quinolinecarboxylic acid with 5 hydrogen bond and bis(2-propylpentyl) phthalate ester showing single hydrogen bond interaction. Trihydroindole has got the highest Vanderwaal interaction followed by bis(2-propylpentyl) phthalate. Dehydrodiisoeugenol showed 2π – σ interactions which is the highest. π – alkyl interactions were found to be greater in trihydroindole. On the other hand, only 3-Quinolinecarboxylic acid showed π – sulfur interactions.

5. Conclusion

The present investigation had documented the presence of *csgA* gene among the ESBL positive *A. baumannii* strains which may be considered as a serious threat in hospital environment. *In-vitro* anti-biofilm activity was promising with the crude extracts of *A.*

Table 1
2D and 3D structures and SMILES format of the selected bio-compounds from *A. indica* for the study















Compound name	2D	3D	SMILES	Mol formula
Imidazole-2-carboxylic acid			<chem>CC1 = CN = C(N1)C(=O)O</chem>	C ₅ H ₅ N ₂ O ₂
bis (2-propylpentyl) phthalate ester			<chem>CCCC(CCC)COC(=O)C1 = CC = CC = C1C(=O)OCC(CCC)CCC</chem>	C ₂₄ H ₃₈ O ₄
Dehydrodiisoeugenol			<chem>CC = CC1 = CC2 = C(C(=C1)OC)OC(C2C)C3 = CC(=C(C = C3)O)OC</chem>	C ₂₀ H ₂₂ O ₄
4-Dehydroxy tyramine			<chem>C1OC2 = C(O1)C = C(C(=C2)C = NCCC3 = CC = CC = C3)[N +](=O)[O-]</chem>	C ₁₆ H ₁₄ N ₂ O ₄
Trihydroindole			<chem>CCOC1 = CC = C(C = C1)C2CC3 = C(C(=C(N3)C(=O)OC(C)C)C(=O)C2</chem>	C ₂₁ H ₂₅ NO ₄
3-Quinolinecarboxylic acid			<chem>CCOC(=O)C1 = CNC2 = C(C1 = O)C = C(C = C2)F</chem>	C ₁₂ H ₉ F ₂ NO ₃
Ceftazidime			<chem>CC(C)(C(=O)O)ON = C(C1 = CSC(=N1)N)C(=O)NC2C3N(C2 = O)C(=C(CS3)C [N +]4 = CC = CC = C4)C(=O)[O-]</chem>	C ₂₂ H ₂₂ N ₆ O ₇ S ₂

Table 2
Molinspiration assessments on *A.indica* bio-compounds for drug likeliness

Compounds	M.wt	Hydrogen Bond Donor	Hydrogen Bond Acceptor	miLogP	Rotatable bonds	nViolations	TPSA (Å)	Volume	N atoms
Imidazole-2-carboxylic acid	126.11	2	4	-0.17	1	0	65.98	104.44	9
bis (2-propylpentyl) phthalate ester	390.56	0	4	8.04	16	1	52.61	407.90	28
Dehydrodiisoeugenol	326.39	1	4	4.10	4	0	47.93	306.90	24
4-Dehydroxy tyramine	298.30	0	6	3.35	5	0	76.66	259.58	22
Trihydroindole	355.43	1	5	4.54	6	0	68.40	335.84	26
3-Quinolinecarboxylic acid	253.20	1	4	0.10	3	0	59.17	203.20	18
Ceftazidime	546.59	4	13	-5.68	9	2	191.23	439.78	37

indica with imidazole-2-carboxylic acid exhibiting a greater interaction with *csgA* using computational analysis. However the study requires further experimental analysis for the design of novel drugs from *A. indica* to combat the menace of biofilm formation in drug resistant strains such as ESBL producers of *A. baumannii*.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.




Fig. 4. Visualizing hydrogen interactions between *csgA* with a. imidazole-2-carboxylic acid b. bis (2-propylpentyl) phthalate ester c. dehydrodiisoeugenol d. 4-dehydroxy tyramine e. trihydroindole f. 3-quinolinecarboxylic acid g. ceftazidime.

Table 3
CsgA protein interactions with bio-active compounds from *A. indica*

Compound name	CsgA		Ligand atoms	Distance (Å)	Docking Energy (Kcal/Mol)
	Residue	Atom			
Imidazole-2-carboxylic acid	ARG185	NH1	N	2.98	-5.66
	ARG185	NE	O	2.76	
	ARG185	N	O	2.86	
	ARG185	N	O	2.96	
	ARG185	O	H	2.26	
	GLY182	O	H	1.90	
	VAL184	N	O	3.17	
bis(2-propylpentyl) phthalate	GLY85	N	O	3.15	-4.07
	SER135	OG	NE2	3.02	
Dehydrodiisoeugenol	SER135	OG	H	2.13	-8.03
	GLN136	NE2	H	2.87	
	ASN83	ND2	O	2.87	
4-Dehydroxy tyramine	LYS155	NZ	O	2.70	-8.9
	LYS155	NZ	O	3.16	
	GLN136	NE2	O	3.18	
Trihydroindole	ASN83	ND2	O	3.11	-9.39
	ILE13	N	O	3.06	
	THR186	OG1	O	3.11	
3-Quinolinecarboxylic acid	ASN83	ND2	O	3.01	-6.94
	ILE13	N	O	3.10	
	LYS155	NZ	F	3.08	
	ASN83	O	H	1.98	
	ARG33	NH2	O	2.97	
Ceftazidime	ARG33	NE	O	2.92	-9.94
	ARG11	NH2	O	3.06	
	TYR151	OH	O	3.07	
	LYS155	NZ	O	2.88	
	GLY85	O	H	2.03	
	GLY85	N	O	2.78	

Table 4
Docking scores of *A. indica* against *csgA* protein of *A. baumannii*

CsgA docking with compounds	Number of hydrogen bonds	Binding energy	Inhibition constant	Ligand efficiency	Intermolecular energy	vdW + Hbond + desolv Energy	Electrostatic energy	Torsional energy	Total internal Unbound
Imidazole-2-carboxylic acid	7	-5.66	70.45	-0.63	-6.26	-5.37	-0.89	0.6	-0.43
bis (2-propylpentyl) phthalate ester	1	-4.07	1.03	-0.15	-8.85	-8.8	-0.04	4.77	-2.64
Dehydrodiisoeugenol	3	-8.03	1.3	-0.33	-9.52	-9.37	-0.15	1.49	-0.31
4-Dehydroxy tyramine	3	-8.9	297.89	-0.4	-10.39	-9.13	-1.26	1.49	-0.99
Trihydroindole	3	-9.39	131.66	-0.36	-11.18	-11.02	-0.16	1.79	-1.13
3-Quinolinecarboxylic acid	5	-6.94	8.12	-0.39	-7.84	-7.58	-0.26	0.89	-0.08
Ceftazidime	7	-9.94	51.46	-0.27	-13.22	-10.81	-2.41	3.28	-2.35

Table 5
Overall interaction of csG A with the bioactive compounds from *A.indica*

CsgA docking with compounds	Hydrogen bonds interactions	van der Waals interactions	π - σ interactions/ amide- π stacked interactions/ π -cation interactions	alkyl/ π -alkyl interactions	π -sulfur interaction
Imidazole-2-carboxylic acid	7	4	1	1	–
bis (2-propylpentyl) phthalate ester	1	7	–	4	–
Dehydroiisoeugenol	3	3	2	5	–
4-Dehydroxy tyramine	3	6	–	3	–
Trihydroindole	3	9	1	8	–
3-Quinolincarboxylic acid	5	3	1	6	1
Ceftazidime	7	14	1	5	–

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jksus.2020.09.025>.

References

Alzohairy, M.A., 2016. Therapeutics role of *Azadirachta indica* (Neem) and their active constituents in diseases prevention and treatment. *Evid.-Based Complement. Altern. Med.* 2016, 1–11.

Avila-Novoa, M.-G. et al. (2019) 'Biofilm Formation and Detection of Fluoroquinolone- and Carbapenem-Resistant Genes in Multidrug-Resistant *Acinetobacter baumannii*', *The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale / AMMI Canada*, 2019, p. 3454907.

Barnhart, M.M., Chapman, M.R., 2006. Curli biogenesis and function. *Annu. Rev. Microbiol.* 60 (1), 131–147.

Będzichowska, A., Przekora, J., Stapińska-Syniec, A., Guzek, A., Murawski, P., Jobs, K., Wróblewska, B., Kalicki, B., 2019. Frequency of infections caused by ESBL-producing bacteria in pediatric ward – single center five-year observation. *AOMS* 15 (3), 688–693.

Beijerinck, M., 1911. Pigmenten als oxydatieproducten gevormd door bacterien. *Versl Koninklijke Akad Wetensch Amsterdam* 19, 1092–1103.

Benet, L.Z., Hosey, C.M., Ursu, O., Oprea, T.I., 2016. BDDCS, the Rule of 5 and drugability. *Adv. Drug Deliv. Rev.* 101, 89–98.

Boyce, J.M., 2007. Environmental contamination makes an important contribution to hospital infection. *J. Hosp. Infect.* 65, 50–54.

Cerqueira, G.M., Peleg, A.Y., 2011. Insights into *Acinetobacter baumannii* pathogenicity. *IUBMB Life* 63 (12), 1055–1060.

Chaichoowong, S., Bernd Bol, J., Bol, P., Gamse, T., Sriariyanun, M., 2017. Chemical profiling of *acalypha indica* obtained from supercritical carbon dioxide extraction and soxhlet extraction methods. *Orient. J. Chem* 33 (1), 66–73.

da Costa, J.T., Forim, M.R., Costa, E.S., De Souza, J.R., Mondego, J.M., Boiça Junior, A.L., 2014. Effects of different formulations of neem oil-based products on control *Zabrotes subfasciatus* (Boheman, 1833) (Coleoptera: Bruchidae) on beans. *J. Stored Prod. Res.* 56, 49–53.

D'Agata, E. M. et al. (1999) 'Molecular epidemiology of ceftazidime-resistant gram-negative bacilli on inanimate surfaces and their role in cross-transmission during nonoutbreak periods', *Journal of clinical microbiology*, 37(9), pp. 3065–3067.

Darvishi, M. (2016) 'Virulence Factors Profile and Antimicrobial Resistance of *Acinetobacter baumannii* Strains Isolated from Various Infections Recovered from Immunosuppressive Patients', *Biomedical and Pharmacology Journal*, pp. 1057–1062. doi: 10.13005/bpj/1048.

Daryanavard, R., Safaei, H.R., 2015. Virulence genes and antimicrobial resistance properties of *Acinetobacter baumannii* isolated from pediatrics suffered from UTIs. *Int. J. Adv. Res. Biol. Sci.* 2 (11), 272–279.

Gowrishankar, S. et al., 2016. Cyclic dipeptide cyclo(L-leucyl-L-prolyl) from marine *Bacillus amyloliquefaciens* mitigates biofilm formation and virulence in *Listeria monocytogenes*. *Pathogens Disease* 74 (4), p. ftw017.

Hammar, M., Bian, Z., Normark, S., 1996. Nucleator-dependent intercellular assembly of adhesive curli organelles in *Escherichia coli*. *Proc. Natl. Acad. Sci.* 93 (13), 6562–6566.

Hammer, N.D., Schmidt, J.C., Chapman, M.R., 2007. The curli nucleator protein, CsgB, contains an amyloidogenic domain that directs CsgA polymerization. *Proc. Natl. Acad. Sci.* 104 (30), 12494–12499.

Jain, N., Adén, J., Nagamatsu, K., Evans, M.L., Li, X., McMichael, B., Ivanova, M.I., Almqvist, F., Buxbaum, J.N., Chapman, M.R., 2017. Inhibition of curli assembly and *Escherichia coli* biofilm formation by the human systemic amyloid precursor transthyretin. *Proc Natl Acad Sci USA* 114 (46), 12184–12189.

Jawad, A. et al. (1996) 'Influence of relative humidity and suspending menstrua on survival of *Acinetobacter* spp. on dry surfaces', *Journal of clinical microbiology*, 34(12), pp. 2881–2887.

Jawad, A., Snelling, A.M., Heritage, J., Hawkey, P.M., 1998a. Exceptional desiccation tolerance of *Acinetobacter radioresistens*. *J. Hosp. Infect.* 39 (3), 235–240.

Jawad, A., Seifert, H., et al. (1998) 'Survival of *Acinetobacter baumannii* on dry surfaces: comparison of outbreak and sporadic isolates', *Journal of clinical microbiology*, 36(7), pp. 1938–1941.

Kelleher, B.P., Broin, S.D., 1991. Microbiological assay for vitamin B12 performed in 96-well microtitre plates. *J. Clin. Pathol.* 44 (7), 592–595.

Kouidhi, B., Zmantar, T., Hentati, H., Bakhrouf, A., 2010. Cell surface hydrophobicity, biofilm formation, adhesives properties and molecular detection of adhesin genes in *Staphylococcus aureus* associated to dental caries. *Microb. Pathog.* 49 (1-2), 14–22.

Mistry, K.S., Sanghvi, Z., Parmar, G., Shah, S., 2014. The antimicrobial activity of *Azadirachta indica*, *Mimosa elengi*, *Tinospora cardifolia*, *Ocimum sanctum* and 2% chlorhexidine gluconate on common endodontic pathogens: an in vitro study. *Eur. J. Dent.* 08 (02), 172–177.

Momtaz, H., Seifati, S.M., Tavakol, M., 2015. Determining the prevalence and detection of the most prevalent virulence genes in *Acinetobacter baumannii* isolated from hospital infections. *Int. J. Med. Lab. 2* (2), 87–97.

Montefour, K. et al. (2008) '*Acinetobacter baumannii*: an emerging multidrug-resistant pathogen in critical care', *Critical care nurse*, 28(1), pp. 15–25; quiz 26.

Rawat, D., Nair, D., 2010. Extended-spectrum β -lactamases in gram negative bacteria. *J. Global Infect. Dis.* 2 (3), 263. <https://doi.org/10.4103/0974-777X.68531>.

Rice, L., 2008. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. *J. Infect. Dis.* 197 (8), 1079–1081.

Russotto, V. et al., 2015. Bacterial contamination of inanimate surfaces and equipment in the intensive care unit. *J. Intensive Care Med.* 3, 54.

Sánchez, E. et al., 2016. Antibacterial and antibiofilm activity of methanolic plant extracts against nosocomial microorganisms. *Evid.-based Complement. Altern. Med.*: eCAM 2016, 1572697.

Singaravelu, S., Sankarapillai, J., Sasidhar Chandrakumari, A., Sinha, P., 2019. Effect of *Azadirachta indica* crude bark extracts concentrations against gram-positive and gram-negative bacterial pathogens. *J. Pharm. Bioall. Sci.* 11 (1), 33. <https://doi.org/10.4103/JPBS.JPBS.150.18>.

Smiline, A.S.G., Vijayashree, J.P., Paramasivam, A., 2018. Molecular characterization of plasmid-encoded blaTEM, blaSHV and blaCTX-M among extended spectrum β -lactamases [ESBLs] producing *Acinetobacter baumannii*. *Br. J. Biomed. Sci.* 75 (4), 200–202.

Sudevan, S., Vidyamol, K.K., Ranganayaki, P., Vijayarghavan, R., 2013. Phytochemical extraction and antimicrobial properties of *azadirachta indica* (neem). *Glob. J. Pharmacol.* 7, 316–320. <https://doi.org/10.5829/jidosi.gjp.2013.7.3.1107>.

Tavakol, M. et al., 2018. Genotyping and distribution of putative virulence factors and antibiotic resistance genes of *Acinetobacter baumannii* strains isolated from raw meat. *Antimicrob. Resist. Infect. Control* 7, 120.

Zeighami, H. et al., 2019. Virulence characteristics of multidrug resistant biofilm forming *Acinetobacter baumannii* isolated from intensive care unit patients. *BMC Infect. Dis.* 19 (1), 629.